Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare coverage of investigational devices with "incremental risk" to begin Nov. 1.

This article was originally published in The Gray Sheet

Executive Summary

MEDICARE COVERAGE OF INVESTIGATIONAL DEVICES PRESENTING "INCREMENTAL RISK" relative to an approved device will begin Nov. 1, 1995. Faced with pressure from Capitol Hill, the medical device and hospital industries, and physicians, HCFA plans to issue a final rule in the Sept. 19 Federal Register that partially reverses its policy of refusing to pay for unapproved devices in investigational device exemption trials. There will be a 60-day comment period on the final rule.

You may also be interested in...



CMS Should Clarify Coverage For Device Trials, Manufacturers Say

Device manufacturers are asking for a clearer path to Medicare coverage of their clinical studies

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Latest Headlines
See All
UsernamePublicRestriction

Register

MT004719

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel